Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes (original) (raw)

“…Also, lifestyle interventions do not reduce cardiovascular events despite weight loss and improved glycemic control (17). The real-world value of newly developed antidiabetic medication such as glucagon-like protein (GLP-1) agonists, the dipeptidyl peptidase-4 inhibitors or sodium/glucose cotransporter 2-blockers, which have shown some promise in at least some subgroups of diabetic patients, still needs to be determined (18,19,20). Regarding NAFLD, and in particular NASH, the mainstay of therapy remains lifestyle changes since no effective medical treatment has yet been introduced (3,21,22,23).…”